ClinicalTrials.gg
TerminatedNCT04241835Updated Nov 13, 2026Results posted

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

A Phase 1 interventional study of Tazemetostat in Hepatic Impairment and Advanced Malignant Solid Tumor, sponsored by Epizyme, Inc.. Terminated at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Epizyme, Inc. (part of Ipsen) · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor's decision to discontinue tazemetostat treatment based on emerging safety data from another clinical trial indicating there may be an unfavourable benefit-risk profile.
Updated Nov 13, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the study drug tazemetostat.

The pharmacokinetics of the study drug in participants with advanced solid tumors and moderate or severe hepatic (liver) impairment will be compared with participants with advanced malignancies and normal hepatic function.

An advanced malignancy is a cancer that has recurred (come back) after prior treatment or hasn't controlled with treatment.

The trial will also study the safety of the study drug in participants (how well it is tolerated).

Read the detailed description

The study will be conducted in 2 parts for subjects with advanced malignancies and either normal liver function, or advanced malignancies and moderate, or severe hepatic impairment. Subjects in Part 1 of the study will receive a single oral, 800 mg dose of tazemetostat on Day 1 and Day 15. In addition, the subjects will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily from Day 5 to Day 14. Blood samples for PK analysis will be obtained on Day 1 through Day 4 and again on Day 15 through Day 18. Part 1 ends on Day 18.

Subjects continuing treatment in Part 2 will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily in repeated 28-day cycles beginning on Day 19 until Investigator-assessed clinical progression per standard practice, or unacceptable toxicity, or until another discontinuation criterion is met. Subjects must have an end of study visit for safety assessment 30 days after the last dose of tazemetostat or prior to initiation of a subsequent anticancer therapy, whichever occurs first. Supplementary study conduct information not mandated to be present in this protocol is provided in the accompanying procedure manuals (i.e., laboratory, pharmacy, ECG manuals). Such manuals will provide the site personnel with administrative and detailed technical information that does not impact subject safety.

02

Conditions studied

  • Hepatic Impairment
  • Advanced Malignant Solid Tumor
03

In context

Lead sponsor

Epizyme, Inc. is the lead sponsor of 21 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.

First submitted before Epizyme, Inc. became part of Ipsen.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 18 years age at the time of consent.
  2. (ECOG) performance status 0 to 2.
  3. Has the ability to understand and provided signed written informed consent.
  4. of > 3 months.
  5. and/or cytologically confirmed advanced or unresectable solid tumors has progressed after treatment for which there are no standard therapies available OR histologically and/or cytologically confirmed hematological that have , or refractory disease following at least 2 standard for which there are no standard therapies available.
  6. Must have evaluable or .
  7. Has all prior treatment (i.e., chemotherapy, immunotherapy, radiotherapy) related toxicities resolve to ≤ Grade 1 per , Version 5.0 or are clinically stable and not clinically significant, at time of consent.
  8. All subjects must have completed any prior chemotherapy, targeted therapy and major surgery, ≥ 28 days before study entry. For daily or weekly chemotherapy without the potential for delayed toxicity, a of 14 days may be acceptable, and questions related to this can be discussed with the Medical Monitor.
  9. Has adequate hematologic (bone marrow [BM] and coagulation factors), and renal function.
  10. Able to swallow and retain orally-administered medication and without clinically significant gastrointestinal abnormalities that could alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
  11. Subjects with abnormal hepatic function will be eligible and will be grouped according to established criteria. Subjects with active hemolysis will be excluded.
  12. Manual differential with no significant morphologic abnormalities on complete blood count (CBC) testing.
  13. Male subjects must have had a successful vasectomy OR must either practice complete abstinence or agree to use a latex or synthetic condom during sexual contact with a female of from the first dose of study drug, during study treatment (including during dose interruptions), and for 3 months after study drug discontinuation.
  14. Females of childbearing potential must have a negative serum pregnancy test at screening and within 24 hours prior to the first dose of study drug. All females will be considered of childbearing potential unless they are naturally or have been sterilized.
  15. Females of childbearing potential (FCBP) must either practice complete abstinence or agree to use a highly effective method of beginning at least 28 days prior to the first dose of study drug, during study treatment (including during dose interruptions), and for 6 months after study drug discontinuation.
  16. Has a corrected by Fridericia's formula (QTcF) ≤480 msec.
  17. Subjects with diagnosed (HIV) are eligible to participate in the study if they meet established criteria.

Exclusion criteria

Exclusion Criteria:

  1. Prior exposure to tazemetostat or other inhibitor(s) of EZH2.
  2. Symptomatic or untreated or or spinal cord compression as documented by CT or MRI scan, analysis of cerebrospinal fluid or neurological exam. Subjects with primary glioblastoma multiforme are excluded.
  3. bleeding diathesis or coagulopathy, including known function disorders. Subjects on anticoagulation with low molecular weight heparin are allowed.
  4. Known to any of the components of tazemetostat.
  5. Concurrent agent or anticancer therapy. NOTE: Megestrol (Megace) if used as an appetite stimulant is allowed.
  6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements.
  7. Have a known active infection with virus (HBV, as measured by positive hepatitis B surface antigen, virus (HCV, as measured by positive hepatitis C antibody), OR human T-cell lymphotropic virus 1.
  8. Subjects taking medications that are known potent inducers/inhibitors (including St. John's Wort).
  9. Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from 24 hours prior to the first dose of study drug until the last dose of study drug.
  10. Any condition or medical problem in addition to the underlying and organ dysfunction that the Investigator feels would pose unacceptable risk.
  11. Has thrombocytopenia, neutropenia, or anemia of grade ≥3 (per 5.0 criteria) or any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS).
  12. Has abnormalities known to be associated with MDS and myeloproliferative neoplasms (MPN) observed in cytogenetic testing and DNA sequencing.
  13. Has a prior history of T-LBL/T-ALL.
  14. Ingestion of alcohol and smoking is not permitted any time during the study.
  15. History of drug abuse (including alcohol) within the last 6 months prior to screening.
  16. Severe hepatic encephalopathy (Grade >2) or degree of CNS impairment which the Investigator considers sufficiently serious to interfere with the , the conduct, the completion, or the results of this trial, or constitutes an unacceptable risk to the subject.
  17. History of liver transplantation.
  18. Advanced ascites or ascites that require drainage and albumin supplementation, as judged by the Investigator.
  19. Acute damage of the liver with Grade 4 /ALT values at screening or admission.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Open label Tazemetostat

    Part 1: Participants will receive a single oral 800 mg dose on day 1, and twice daily from day 5 to day 14. Participants will return to the clinical study unit on an out-patient basis from day 15 to day 18. A single oral 800 mg dose of tazemetostat will be administered on day 15. Part 2: Will begin on day 19 and participants continuing treatment in Part 2 will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily in repeated 28-day cycles.

    Drug: Tazemetostat

Interventions

  • Tazemetostat (EPZ-6438) in tablet form at a dose of 800 mg once daily on days 1 and 15 and twice daily on days 5 to 14 of the first 28-day cycle. Participants may continue tazemetostat treatment at 800 mg twice daily in additional 28-day cycles until progression or unacceptable toxicity.

    Also known as: EPZ-6438, IPN60200, Tazverik®

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) of Tazemetostat and EPZ-6930 Following Single Dose Administration

    Blood samples were collected at specified timepoints for the assessment of AUC0-t of tazemetostat and its metabolite EPZ-6930 following single dose administration. Pharmacokinetic (PK) parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)

  2. Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration

    Blood samples were collected at specified timepoints for the assessment of AUC0-t of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)

  3. Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Tazemetostat and EPZ-6930 Following Single Dose Administration

    Blood samples were collected at specified timepoints for the assessment of AUC0-inf of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)

  4. Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Single Dose Administration

    Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)

  5. Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Multiple Doses Administration

    Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)

  6. Part 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Single Dose Administration

    Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)

  7. Part 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration

    Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)

  8. Part 1: Observed Time at Maximum Plasma Concentration (Tmax) of Tazemetostat and EPZ-6930 Following Single Dose Administration

    Blood samples were collected at specified timepoints for the assessment of tmax of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)

  9. Part 1: Observed Time at Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration

    Blood samples were collected at specified timepoints for the assessment of tmax of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)

  10. Part 1: Terminal Elimination Half-Life (t1/2) of Tazemetostat and EPZ-6930 Following Single Dose Administration

    Blood samples were collected at specified timepoints for the assessment of t1/2 of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)

  11. Part 1: Terminal Elimination Half-Life of Tazemetostat and EPZ-6930 Following Multiple Doses Administration

    Blood samples were collected at specified timepoints for the assessment of t1/2 of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)

  12. Part 1: Unbound Fraction of Tazemetostat and EPZ-6930 in Plasma (fu)

    Blood samples were collected at specified timepoints for the assessment of fu of tazemetostat and its metabolite EPZ-6930 following single dose and multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

    Time frame: Pre-dose (0 hour) on Day 15; 3 hours post-dose on Days 1 and 15 of Cycle 1 (each cycle was 28 days)

Secondary outcomes

  1. Parts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily have a causal relationship with this study drug. A serious AE was an AE that occurred during any study phase (i.e., baseline, treatment, washout, or follow-up), and at any dose of the study drug, comparator, or placebo, that fulfilled one or more of the following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect or was an important medical event that jeopardized the participant or required medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the day of the first dose of study drug through 30 days after the end of study drug.

    Time frame: From first dose of study drug (Day 1) up to 30 days after last dose of study drug, approximately 78 weeks

07

Results

Posted Nov 13, 2026
Limitations and caveats
The severe hepatic impairment cohort was deemed non-feasible to enroll. In addition, the study was terminated before planned enrollment was completed and following the Sponsor's decision to discontinue tazemetostat treatment in all active clinical trials and expanded access programs based on emerging safety data from another clinical trial indicating there may be an unfavourable benefit-risk profile.

Participant flow

This phase I, 2-part, open-label study was conducted in participants with either advanced solid tumors, or hematological malignancies and normal hepatic function or moderate, or severe hepatic impairment at 18 sites in 5 countries. Study was terminated following Sponsor's decision to discontinue tazemetostat treatment in all active clinical trials and expanded access programs based on emerging safety data from another clinical trial indicating there may be an unfavourable benefit-risk profile.

Participant flow — Overall Study
MilestoneNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Started108
Participants entered part 294
Completed00
Not completed108
Withdrew: Radiologic progression53
Withdrew: Withdrawal by subject22
Withdrew: Clinical progression11
Withdrew: Unacceptable toxicity/adverse event11
Withdrew: Death10
Withdrew: Other01

Outcome measures

PrimaryPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) of Tazemetostat and EPZ-6930 Following Single Dose Administration

Blood samples were collected at specified timepoints for the assessment of AUC0-t of tazemetostat and its metabolite EPZ-6930 following single dose administration. Pharmacokinetic (PK) parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Reported as:
Mean · hour*nanogram per milliliter (h*ng/mL)
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) of Tazemetostat and EPZ-6930 Following Single Dose Administration
hour*nanogram per milliliter (h*ng/mL)Normal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat8030 ± 699013900 ± 3570
EPZ-69307520 ± 35808060 ± 3270
PrimaryPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration

Blood samples were collected at specified timepoints for the assessment of AUC0-t of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
Reported as:
Mean · h*ng/mL
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
h*ng/mLNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat4520 ± 17909550 ± 5040
EPZ-693011100 ± 436013600 ± 4310
PrimaryPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Tazemetostat and EPZ-6930 Following Single Dose Administration

Blood samples were collected at specified timepoints for the assessment of AUC0-inf of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Reported as:
Mean · h*ng/mL
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Tazemetostat and EPZ-6930 Following Single Dose Administration
h*ng/mLNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat8050 ± 699014000 ± 3600
EPZ-69307590 ± 36208210 ± 3310
PrimaryPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Single Dose Administration

Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Reported as:
Mean · h*ng/mL
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Single Dose Administration
h*ng/mLNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat5700 ± 44407580 ± 2120
EPZ-69304020 ± 18803360 ± 1600
PrimaryPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Multiple Doses Administration

Blood samples were collected at specified timepoints for the assessment of AUC0-8 of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
Reported as:
Mean · h*ng/mL
Part 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
h*ng/mLNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat3290 ± 14905720 ± 2530
EPZ-69306140 ± 21907390 ± 2110
PrimaryPart 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Single Dose Administration

Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Reported as:
Mean · ng/mL
Part 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Single Dose Administration
ng/mLNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat1580 ± 10302020 ± 725
EPZ-6930868 ± 425714 ± 387
PrimaryPart 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration

Blood samples were collected at specified timepoints for the assessment of Cmax of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
Reported as:
Mean · ng/mL
Part 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
ng/mLNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat1120 ± 5591850 ± 772
EPZ-69301400 ± 5871560 ± 568
PrimaryPart 1: Observed Time at Maximum Plasma Concentration (Tmax) of Tazemetostat and EPZ-6930 Following Single Dose Administration

Blood samples were collected at specified timepoints for the assessment of tmax of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Reported as:
Median · hour
Part 1: Observed Time at Maximum Plasma Concentration (Tmax) of Tazemetostat and EPZ-6930 Following Single Dose Administration
hourNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat1.50 (0.950 to 6.10)1.78 (0.967 to 5.83)
EPZ-69301.97 (1.43 to 7.75)2.97 (1.45 to 5.97)
PrimaryPart 1: Observed Time at Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration

Blood samples were collected at specified timepoints for the assessment of tmax of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
Reported as:
Median · hour
Part 1: Observed Time at Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
hourNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat1.45 (0.967 to 4.00)1.00 (0.950 to 1.50)
EPZ-69301.93 (1.05 to 4.00)1.50 (0.983 to 3.77)
PrimaryPart 1: Terminal Elimination Half-Life (t1/2) of Tazemetostat and EPZ-6930 Following Single Dose Administration

Blood samples were collected at specified timepoints for the assessment of t1/2 of tazemetostat and its metabolite EPZ-6930 following single dose administration. PK parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
Reported as:
Mean · hour
Part 1: Terminal Elimination Half-Life (t1/2) of Tazemetostat and EPZ-6930 Following Single Dose Administration
hourNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat6.37 ± 1.0010.9 ± 4.62
EPZ-693011.0 ± 4.0613.6 ± 3.93
PrimaryPart 1: Terminal Elimination Half-Life of Tazemetostat and EPZ-6930 Following Multiple Doses Administration

Blood samples were collected at specified timepoints for the assessment of t1/2 of tazemetostat and its metabolite EPZ-6930 following multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
Reported as:
Mean · hour
Part 1: Terminal Elimination Half-Life of Tazemetostat and EPZ-6930 Following Multiple Doses Administration
hourNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat10.3 ± 5.0316.7 ± 9.21
EPZ-693015.2 ± 3.8218.1 ± 6.87
PrimaryPart 1: Unbound Fraction of Tazemetostat and EPZ-6930 in Plasma (fu)

Blood samples were collected at specified timepoints for the assessment of fu of tazemetostat and its metabolite EPZ-6930 following single dose and multiple doses administration (at steady state). PK parameters were assessed using non-compartmental data analysis method.

Time frame:
Pre-dose (0 hour) on Day 15; 3 hours post-dose on Days 1 and 15 of Cycle 1 (each cycle was 28 days)
Reported as:
Mean · ratio
Part 1: Unbound Fraction of Tazemetostat and EPZ-6930 in Plasma (fu)
ratioNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Tazemetostat: Day 1: 3 hours post-dose0.122 ± 0.02430.126 ± 0.0253
Tazemetostat: Day 15: Pre-dose0.114 ± 0.01920.118 ± 0.0180
Tazemetostat: Day 15: 3 hours post-dose0.117 ± 0.02420.124 ± 0.0168
EPZ-6930: Day 1: 3 hours post-dose0.412 ± 0.06430.421 ± 0.0621
EPZ-6930: Day 15: Pre-dose0.394 ± 0.04960.385 ± 0.0662
EPZ-6930: Day 15: 3 hours post-dose0.393 ± 0.07640.418 ± 0.0462
SecondaryParts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a medicinal product and which did not necessarily have a causal relationship with this study drug. A serious AE was an AE that occurred during any study phase (i.e., baseline, treatment, washout, or follow-up), and at any dose of the study drug, comparator, or placebo, that fulfilled one or more of the following: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, was a congenital abnormality or birth defect or was an important medical event that jeopardized the participant or required medical intervention to prevent one of the outcomes listed above. TEAEs were AEs that started or worsened in severity on or after the day of the first dose of study drug through 30 days after the end of study drug.

Time frame:
From first dose of study drug (Day 1) up to 30 days after last dose of study drug, approximately 78 weeks
Reported as:
Count of participants · Participants
Parts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Any TEAE107
Any TESAE35

Adverse events

Collected over AEs were collected from first dose of study drug (Day 1) up to 30 days after last dose of study drug, approximately 78 weeks. Deaths were collected from first dose of study drug (Day 1) up to end of follow up for death for each participant, approximately 269 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Normal Hepatic Function Cohort4/10 (40%)3/10 (30%)10/10 (100%)
Moderate Hepatic Impairment Cohort3/8 (37.5%)5/8 (62.5%)7/8 (87.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
Cholangitis acuteHepatobiliary disorders0/101/8
CholangitisHepatobiliary disorders0/101/8
JaundiceHepatobiliary disorders0/101/8
SepsisInfections and infestations0/101/8
Intracranial tumour haemorrhageNervous system disorders0/101/8
Status epilepticusNervous system disorders0/101/8
General physical health deteriorationGeneral disorders0/101/8
HypokalaemiaMetabolism and nutrition disorders0/101/8
COVID-19 pneumoniaInfections and infestations1/100/8
Atrial fibrillationCardiac disorders1/100/8
Most frequent other events
Showing 10 of 68
Most frequent other events
EventNormal Hepatic Function CohortModerate Hepatic Impairment Cohort
NauseaGastrointestinal disorders1/104/8
DizzinessNervous system disorders3/100/8
Abdominal painGastrointestinal disorders1/102/8
VomitingGastrointestinal disorders0/102/8
HypokalaemiaMetabolism and nutrition disorders0/102/8
ThrombocytopeniaBlood and lymphatic system disorders1/102/8
Blood alkaline phosphatase increasedInvestigations0/102/8
HyperbilirubinaemiaHepatobiliary disorders0/102/8
FatigueGeneral disorders2/100/8
Decreased appetiteMetabolism and nutrition disorders2/100/8

Baseline characteristics

Safety population consisted of all participants who received at least one dose or partial dose of study drug.

Age, Continuous
Age, Continuous(years)Normal Hepatic Function CohortModerate Hepatic Impairment CohortTotal
Mean64.3 ± 12.0663.1 ± 8.7663.8 ± 10.43
Sex: Female, Male
Sex: Female, Male(Participants)Normal Hepatic Function CohortModerate Hepatic Impairment CohortTotal
Female224
Male8614
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Normal Hepatic Function CohortModerate Hepatic Impairment CohortTotal
Hispanic or Latino303
Not Hispanic or Latino7512
Unknown or Not Reported033
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Normal Hepatic Function CohortModerate Hepatic Impairment CohortTotal
White8513
Black or African American101
Other011
Not Reported123
08

Study locations

14 sites
  • Florida Cancer Specialists & Research Institute
    Lake Mary, Florida 32746, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
  • Hematology Oncology Consultants
    Royal Oak, Michigan 48073, United States
  • Comprehensive Cancer Center of Nevada
    Las Vegas, Nevada 89014, United States
  • Rutgers Cancer Institute
    New Brunswick, New Jersey 08901, United States
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
  • Mary Crowley Cancer Research
    Dallas, Texas 75230, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Antwerp University Hospital
    Edegem, Antwerp 2650, Belgium
  • Institut Bergonie
    Bordeaux, 33076, France
  • Centre Oscar Lambret
    Lille, 59020, France
  • Institut de Cancérologie Strasbourg Europe
    Strasbourg, France
  • MedPolonia
    Poznan, Greater Poland Voivodeship 60693, Poland
  • Summit Clinical Research, s.r.o
    Bratislava, 831 01, Slovakia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Mar 2025, 61 months.

Results were first posted in Nov 2026, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2019
First posted
Jan 27, 2020
StartActual
Jan 15, 2020
Primary completionActual
Mar 12, 2025
CompletionActual
Mar 12, 2025
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Why stopped
Sponsor's decision to discontinue tazemetostat treatment based on emerging safety data from another clinical trial indicating there may be an unfavourable benefit-risk profile.
Nov 13, 2026
Results
Results posted
posted Nov 13, 2026
Primary outcomes
2 edited, 10 added, 5 removed
What changed in the outcomes
  • EditedTo evaluatePart 1: Area Under the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-t: area under the plasma concentration-time curve from timePlasma Concentration-Time Curve From Time 0 to the timeTime of the last quantifiable concentrationLast Quantifiable Concentration (AUC0-t) of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: 0 to 72 hours post dose on Day 1 and Day 15 → Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
  • EditedTo evaluatePart 1: Area Under the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-8: area under the plasma concentration-time curve from timePlasma Concentration-Time Curve From Time 0 to 8 hours post doseHours Post-Dose of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: 0 to 8 hours post dose on Day 1 and Day 15 → Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
  • AddedPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
  • AddedPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
  • AddedPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Multiple Doses AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
  • AddedPart 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
  • AddedPart 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
  • AddedPart 1: Observed Time at Maximum Plasma Concentration (Tmax) of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
  • AddedPart 1: Observed Time at Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
  • AddedPart 1: Terminal Elimination Half-Life (t1/2) of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
  • AddedPart 1: Terminal Elimination Half-Life of Tazemetostat and EPZ-6930 Following Multiple Doses AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
  • AddedPart 1: Unbound Fraction of Tazemetostat and EPZ-6930 in Plasma (fu)Time frame: Pre-dose (0 hour) on Day 15; 3 hours post-dose on Days 1 and 15 of Cycle 1 (each cycle was 28 days)
  • RemovedTo evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-∞: area under the plasma concentration-time curve from time 0 extrapolated to infinityTime frame: 0 to 72 hours post dose on Day 1 and Day 15
  • RemovedTo evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Cmax: observed maximum plasma concentrationTime frame: 0 to 72 hours post dose on Day 1 and Day 15
  • RemovedTo evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Tmax: observed time at CmaxTime frame: 0 to 72 hours post dose on Day 1 and Day 15
  • RemovedTo evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, t1/2: terminal elimination half-lifeTime frame: 0 to 72 hours post dose on Day 1 and Day 15
  • RemovedTo evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, fu: unbound fraction of drug in plasmaTime frame: Pre-dose, 3 hours, 24 hours, and 72 hours post-dose
Nov 13, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore To evaluate the number of participants with adverse events (AEs) as assessed by CTCAE v5.0Now Parts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: Through study completion, an average of 1 year → From first dose of study drug (Day 1) up to 30 days after last dose of study drug, approximately 78 weeks
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Why stopped Sponsor's decision to discontinue tazemetostat treatment based on emerging safety data from another clinical trial indicating there may be an unfavourable benefit-risk profile.
    Results posted
    Primary outcomes 2 edited, 10 added, 5 removed
    What changed in the outcomes
    • EditedTo evaluatePart 1: Area Under the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-t: area under the plasma concentration-time curve from timePlasma Concentration-Time Curve From Time 0 to the timeTime of the last quantifiable concentrationLast Quantifiable Concentration (AUC0-t) of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: 0 to 72 hours post dose on Day 1 and Day 15 → Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
    • EditedTo evaluatePart 1: Area Under the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-8: area under the plasma concentration-time curve from timePlasma Concentration-Time Curve From Time 0 to 8 hours post doseHours Post-Dose of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: 0 to 8 hours post dose on Day 1 and Day 15 → Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
    • AddedPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
    • AddedPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
    • AddedPart 1: Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post-Dose of Tazemetostat and EPZ-6930 Following Multiple Doses AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6 and 8 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
    • AddedPart 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
    • AddedPart 1: Observed Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
    • AddedPart 1: Observed Time at Maximum Plasma Concentration (Tmax) of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
    • AddedPart 1: Observed Time at Maximum Plasma Concentration of Tazemetostat and EPZ-6930 Following Multiple Doses AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
    • AddedPart 1: Terminal Elimination Half-Life (t1/2) of Tazemetostat and EPZ-6930 Following Single Dose AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 1 of Cycle 1 (each cycle was 28 days)
    • AddedPart 1: Terminal Elimination Half-Life of Tazemetostat and EPZ-6930 Following Multiple Doses AdministrationTime frame: Pre-dose (0 hour), 0.5, 1, 1.5, 2, 4, 6, 8, 24, 36, 48 and 72 hours post-dose on Day 15 of Cycle 1 (each cycle was 28 days)
    • AddedPart 1: Unbound Fraction of Tazemetostat and EPZ-6930 in Plasma (fu)Time frame: Pre-dose (0 hour) on Day 15; 3 hours post-dose on Days 1 and 15 of Cycle 1 (each cycle was 28 days)
    • RemovedTo evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-∞: area under the plasma concentration-time curve from time 0 extrapolated to infinityTime frame: 0 to 72 hours post dose on Day 1 and Day 15
    • RemovedTo evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Cmax: observed maximum plasma concentrationTime frame: 0 to 72 hours post dose on Day 1 and Day 15
    • RemovedTo evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Tmax: observed time at CmaxTime frame: 0 to 72 hours post dose on Day 1 and Day 15
    • RemovedTo evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, t1/2: terminal elimination half-lifeTime frame: 0 to 72 hours post dose on Day 1 and Day 15
    • RemovedTo evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, fu: unbound fraction of drug in plasmaTime frame: Pre-dose, 3 hours, 24 hours, and 72 hours post-dose
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore To evaluate the number of participants with adverse events (AEs) as assessed by CTCAE v5.0Now Parts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: Through study completion, an average of 1 year → From first dose of study drug (Day 1) up to 30 days after last dose of study drug, approximately 78 weeks
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04241835
Lead sponsor
Epizyme, Inc.
Collaborators
Sponsor GmbH
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
Jan 15, 2020
Primary completion
Mar 12, 2025
Completion
Mar 12, 2025
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tazemetostat

Start the discussion